// App-Quantinova.ai

6012 : Neoadjuvant pembrolizumab in surgically resectable, HPV negative, locally advanced head and neck squamous cell carcinoma (HNSCC).

Researchers

Presenter

  • Ravindra Uppaluri

Principal Investigators

  • Tianxiang Lin

  • Brian Nussenbaum

  • Ryan S Jackson

  • Jason Rich

  • Patrik Pipkorn

  • Randal Paniello

  • Wade Thorstad

  • Loren Michel

  • Tenny Mudianto

  • Peter John Oppelt

  • Tanya Marya Wildes

  • Gavin P Dunn

  • Jay F Piccirillo

  • Dorina Kallogjeri

  • Scott Rodig

  • Ian S. Hagemann

  • Rebecca Chernock

  • Douglas Adkins

Medical Centers

  • Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA

  • Washington University School of Medicine, St. Louis, MO

  • Washington University in St Louis, St. Louis, MO

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Dana-Farber Cancer Institute, Boston, MA

  • Department of Pathology and Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA

  • Washington University School of Medicine and Siteman Cancer Center, St. Louis, MO

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02296684

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved